Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF-10832 +/- Pembrolizumab in Advanced Urothelial and NSCLC
NCT05318573Phase 2Active, not recruiting
- Sponsor
- Fujifilm Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- May 2029
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of FF-10832 in urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) (5 arms), sponsored by Fujifilm Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 7 years, Duration of Stable Disease in Monotherapy at 7 years and 1 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
FF-10832
03
Conditions
urothelial carcinoma (UC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05318573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318573.